Advertisement

Topics

NeuroRx, Inc. Company Profile

01:34 EDT 17th June 2019 | BioPortfolio

NeuroRx, Inc. is a privately funded, clinical-stage pharmaceutical company, developing NRX-101, the first oral therapeutic for the treatment of Acute Suicidal Ideation and Behavior (ASIB) in bipolar depression. NeuroRx draws upon 30 years of basic science and clinical expertise in the role of the N-methyl-D-aspartate (NMDA), a receptor that regulates human thought processes, particularly depression and suicidality. Currently, there is no approved drug for patients with suicidal ideation / behavior. Most antidepressants, including the SSRI class, carry an FDA “black box” warning for increased risk of suicide, leaving hospitalization and electroconvulsive therapy (ECT) as the standard-of-care for people with bipolar disorder experiencing a suicidal episode. NeuroRx expects to start its phase 2b/3 clinical study of NRX-101 in a few months.


News Articles [4 Associated News Articles listed on BioPortfolio]

NeuroRx aims to tackle suicide by treating bipolar depression with new therapy

NeuroRx Inc CEO Dr. Jonathan Javitt tells Proactive Investors the privately-held clinical stage biopharma company is focused on preventing suicide by treating bipolar depression with its small molec...

NeuroRx's NRX-101 improves depression and suicidality in Phase II

NeuroRx Presents Phase 2 Efficacy & Safety Data for NRX-101, a Breakthrough Therapy Targeting Suicidal Bipolar Depression

Findings suggest potential for NRX-101 in maintaining remission from Severe Bipolar Depression with Acute Suicidal Ideation following initial stabilization with ketamine ...

NeuroRx Receives FDA Breakthrough Therapy Designation for NRX-101, First Oral Drug Targeting Suicidal Bipolar Depression

First oral Rapid-Acting Antidepressant to be granted Breakthrough Designation NeuroRx, a clinical stage biopharma company focused on the development of Rapid Acting Ant...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [4 Associated Clinical Trials listed on BioPortfolio]

NeuroRx Sequential Therapy for Patients With Severe Bipolar Depression and Suicidal Ideation

NMDA antagonist drugs have increasingly been demonstrated to reduce symptoms of depression and suicidal ideation. NeuroRx has developed a sequential therapy consisting of IV NRX-100 (ketam...

NRX101 for Moderate Bipolar Depression and Suicidal Ideation

NMDA antagonist drugs have increasingly been demonstrated to reduce symptoms of depression and suicidal ideation. NeuroRx has developed NRX-101 (fixed dose combination of D-cycloserine and...

Placebo Controlled Trial of NRX-101 for the Maintenance of Stabilization From Acute Suicidal Ideation and Behavior in Bipolar Depression

NeuroRx is developing NRX-101, a fixed-dose combination oral capsule composed of d-cycloserine (DCS) and lurasidone for the maintenance of remission from Acute Suicidal Ideation (C-SSRS le...

NRX100 vs. Placebo for Stabilization of Acute Suicidal Ideation an Behavior in Bipolar Depression

NMDA antagonist drugs have increasingly been demonstrated to reduce symptoms of depression and suicidal ideation. NeuroRx has developed a sequential therapy consisting of IV NRX-100 (ketam...

Companies [1 Associated Companies listed on BioPortfolio]

NeuroRx, Inc.

NeuroRx, Inc. is a privately funded, clinical-stage pharmaceutical company, developing NRX-101, the first oral therapeutic for the treatment of Acute Suicidal Ideation and Behavio...

More Information about "NeuroRx, Inc." on BioPortfolio

We have published hundreds of NeuroRx, Inc. news stories on BioPortfolio along with dozens of NeuroRx, Inc. Clinical Trials and PubMed Articles about NeuroRx, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of NeuroRx, Inc. Companies in our database. You can also find out about relevant NeuroRx, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bipolar Disorders
Bipolar disorder, also known as manic-depressive illness, is a brain disorder that causes unusual shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks. Over half of Bipolar cases develops before the age of 25. Bipolar ...

Mental Health
Adhd Anorexia Depression Dyslexia Mental Health Psychiatry Schizophrenia Stress Mental health, although not being as obvious as physical health, is very important, causing great unhappiness to those affected, causing add...


Corporate Database Quicklinks



Searches Linking to this Company Record